Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Antiviral Res. 2014 Jan 31;104:84–92. doi: 10.1016/j.antiviral.2014.01.016

Figure 6. Combined T-705 and ribavirin therapies significantly improve survival outcome and reduce viral burden when starting treatment 24 h post-RVFV challenge.

Figure 6

Hamsters were treated p.o. with T-705, ribavirin, or a combination of both compounds starting 24 h post-infection (see Table 1 for detailed description of the treatment regimens). A) Percent survival and day 2 B) serum, C) liver, and D) spleen virus titers are shown. One animal each in the T-705 monotherapy and placebo-treated group succumbed prior to sacrifice on day 2. Unique symbols in each treatment group represent values for the same animal for B-D. *P < 0.05, **P < 0.01, and ***P < 0.001 compared to placebo-treated animals; aP < 0.05, bP < 0.01, cP < 0.001 compared to animals receiving T-705 monotherapy; xP < 0.05, zP < 0.001 compared to hamsters treated only with ribavirin. H (high dose), L (low dose), LD (loading dose).